Sorrento Therapeutics Inc (SRNE)

[dia76ca]

THE ACTION ON OVYDSO IN CHINA HAS BEEN VERY RAPID!
JAN 9. Following a successful Australian safety study in healthy volunteers Sorrento announced the very positive results from a phase 1b trial of OVYDSO in Covid patients in China. They stated that they had applied to Chinese authorities for a phase 3 pivotal trial in 1200 patients.
FEB. 2. Sorrento announced that the first patient had been dosed in a 1200 patient phase 3 trial to be conducted in 40 centers in China.
THIS IS VERY RAPID ACTION!
This trial should enroll very rapidly and results could be available as early as May IMO!
What is Next?
" “We are excited to see the similarities of PK in the China study and the Australian study. The significant antiviral effectiveness and tolerability of OVYDSO in COVID patients suggests this compound will significantly benefit patients and will require no boosting with Ritonavir. We expect to initiate the Phase 3 trial very soon in China(done!), and meanwhile we are engaging with regulatory agencies on a global Phase 2/3 trial design in order to initiate OVYDSO Phase 2/3 trials in Mexico and the U.S. as soon as possible,” stated Henry Ji, Ph.D., Chairman and CEO of Sorrento."
China first, followed by Mexico and the US, will open up an enormous Global market for a safer and far cheaper oral anti-viral to combat Covid.